Pre-surgery medication sits at the center of this dementia and brain health question.
Dexmedetomidine, a sedative originally developed for intensive care settings, now has the strongest clinical evidence as a pre-surgery medication that outperforms midazolam for reducing anxiety — particularly in children facing elective procedures. A meta-analysis of 13 randomized trials involving 1,033 children found that intranasal dexmedetomidine achieved satisfactory sedation at the moment of parent separation in 74% of cases, compared to just 50% for midazolam. It also cut postoperative agitation dramatically, from 40% with midazolam down to 10%, and reduced the need for rescue pain medications from 39% to 20%. For anyone who has watched a child become inconsolable before surgery or emerge from anesthesia thrashing and confused, those numbers represent a meaningful shift in care. This matters beyond pediatrics, too.
In adults, dexmedetomidine has been found equally effective as higher doses of midazolam while causing fewer drops in blood pressure and less respiratory depression — side effects that make midazolam particularly worrisome in older patients or those with compromised lung function. For families navigating dementia care, where surgical procedures sometimes become necessary and the patient may already be disoriented or prone to agitation, the choice of preoperative sedative is not a minor detail. It can shape the entire recovery experience. But dexmedetomidine is not the only contender. Researchers have tested melatonin, pregabalin, gabapentin, ketamine, and even virtual reality headsets against midazolam, with results that range from promising to disappointing. This article walks through the evidence for each alternative, where the age of the patient changes the equation entirely, and what questions are worth raising with an anesthesiologist before any procedure.
Table of Contents
- Why Is There a Push to Find Pre-Surgery Medications That Reduce Anxiety Better Than Midazolam?
- How Dexmedetomidine Compares to Midazolam Across Age Groups
- Why the Melatonin Alternative Fell Short in Clinical Trials
- Pregabalin, Gabapentin, and the Mixed Results of Repurposed Medications
- Virtual Reality and Non-Drug Approaches Show Real Promise
- Where Ketamine Fits — and Why It Is Not the First Choice
- What the Shift Away From Midazolam Means for Surgical Care Going Forward
- Conclusion
- Frequently Asked Questions
Why Is There a Push to Find Pre-Surgery Medications That Reduce Anxiety Better Than Midazolam?
Midazolam has been the default preoperative anxiolytic for decades. It works fast, it is cheap, and anesthesiologists know its pharmacology inside and out. But familiarity has masked real drawbacks. Midazolam belongs to the benzodiazepine class, which means it can cause paradoxical agitation in some patients — the very opposite of its intended effect. It also depresses breathing, a risk that escalates in patients with sleep apnea, obesity, or advanced age. In children, the postoperative agitation rate with midazolam hovers around 40%, meaning nearly half of young patients emerge from surgery in a distressed state that is traumatic for both the child and the parents standing nearby.
The cognitive effects deserve attention as well. Benzodiazepines are associated with anterograde amnesia, which might sound like a benefit — who wants to remember the operating room? — but in older adults and those with existing cognitive impairment, adding a drug that disrupts memory formation is a legitimate concern. Research on postoperative delirium in elderly patients has repeatedly flagged benzodiazepines as a contributing factor. For someone already living with early-stage dementia, a medication that clouds cognition further, even temporarily, can set off days of confusion that family caregivers then have to manage at home. A 2023 systematic review of 11 studies involving 824 children confirmed what individual trials had been suggesting: intranasal dexmedetomidine provided better preoperative sedation at both parent-child separation and anesthesia induction compared to oral midazolam. The review, published in Frontiers in Pediatrics, added weight to the case that the field was ready to move beyond its reliance on benzodiazepines as the automatic first choice.
How Dexmedetomidine Compares to Midazolam Across Age Groups
The evidence for dexmedetomidine is strong but comes with an important caveat that often gets left out of headlines. In preschool children between ages two and six, midazolam actually produced more effective anxiety relief than dexmedetomidine. The advantages of dexmedetomidine were more pronounced in older children, meaning that a blanket recommendation to switch every pediatric patient would be premature and potentially counterproductive. This age-dependent response is not entirely surprising. Dexmedetomidine works through alpha-2 adrenergic receptors, producing sedation that more closely resembles natural sleep than the amnestic fog of benzodiazepines.
Younger children, however, may need the deeper anxiolytic effect that midazolam provides because they lack the cognitive capacity to be calmed by gentle sedation alone — a two-year-old who is terrified of strangers in masks is not going to be soothed by feeling drowsy. For older children who can process reassurance and whose anxiety is more anticipatory than primal, the lighter sedation profile of dexmedetomidine appears to be a better fit. In adults, the comparison shifts again. Dexmedetomidine matched the anxiolytic performance of higher-dose midazolam regimens while producing fewer hemodynamic and respiratory side effects. This profile makes it especially relevant for patients who are already medically fragile — those with heart failure, chronic obstructive pulmonary disease, or neurological conditions where respiratory depression could cascade into serious complications. However, dexmedetomidine can cause bradycardia, and its onset is slower than midazolam when given intranasally, which means the timing of administration has to be planned more carefully.
Why the Melatonin Alternative Fell Short in Clinical Trials
Melatonin seemed like an ideal candidate. It is inexpensive, widely available, has a gentle side-effect profile, and parents are already familiar with it as a sleep aid. The MAGIC trial — a double-blind, randomized, non-inferiority study conducted across 20 UK NHS trusts — set out to determine whether melatonin could match midazolam for calming anxious children before elective surgery. The trial enrolled 110 children, 55 in each arm, between July 2019 and November 2022. The result was unambiguous: melatonin was inferior to midazolam. The adjusted mean difference was 13.1 points on anxiety scores, with a 95% confidence interval of 3.7 to 22.4, favoring midazolam.
The trial was actually stopped early due to recruitment futility, meaning the research team concluded that continuing to enroll patients would not change the outcome. On the safety side, melatonin performed well — no serious adverse events occurred in either group, and the adverse event rate was lower for melatonin at 18% compared to 26% for midazolam. The melatonin arm also cost an average of £46.20 less per patient over the 14-day post-surgery follow-up period. This is a case where safer and cheaper did not translate into effective enough. For families who were hoping melatonin could serve as a gentler alternative — particularly for children with developmental differences or sensitivities to stronger medications — the MAGIC trial’s findings were disappointing. Melatonin may still have a role in reducing general nighttime anxiety in the days leading up to a procedure, but as a direct replacement for midazolam in the preoperative holding area, the evidence does not support it.
Pregabalin, Gabapentin, and the Mixed Results of Repurposed Medications
Pregabalin and gabapentin, both originally developed for seizures and later adopted for nerve pain, have anxiolytic properties that made them logical candidates for preoperative use. In a pediatric day-case surgery trial, pregabalin significantly reduced perioperative anesthetic and analgesic requirements, shortened time spent in the post-anesthesia care unit, and decreased time to extubation compared to midazolam. These are meaningful practical advantages — less time under heavy sedation, faster discharge, and lower total drug burden. Gabapentin has shown targeted promise as well. A blinded randomized controlled trial published in the Canadian Journal of Anesthesia found that gabapentin at 1,200 mg produced clinically significant anxiety reduction in highly anxious female patients before major surgery.
The key phrase is “highly anxious” — gabapentin appeared to work best in patients whose baseline anxiety was already elevated, suggesting it may be most useful as a targeted intervention rather than a routine premedication for everyone. However, the picture is not uniformly positive. A 2023 randomized controlled trial published in Scientific Reports found that neither pregabalin nor diazepam significantly reduced preoperative anxiety compared to placebo, despite both drugs increasing sedation levels. In other words, the patients were more sedated but not meaningfully less anxious — a distinction that matters. Being drowsy and being calm are not the same thing, and a medication that achieves one without the other may simply be masking the problem rather than solving it. This study is a useful reminder that sedation scores and anxiety scores measure different things, and conflating them can lead to overconfident conclusions.
Virtual Reality and Non-Drug Approaches Show Real Promise
Not every alternative to midazolam involves swallowing a pill or receiving a nasal spray. A 2024 randomized controlled trial — the ConV2X study — compared an interactive virtual reality underwater game against midazolam in children ages five to eleven undergoing tonsillectomy. The VR group had significantly lower anxiety scores: mYPAS scores of 25.4 plus or minus 4.7 for the VR group versus 32.0 plus or minus 4.9 for the midazolam group, with a p-value of 0.04. This is a notable result because it achieved better anxiety reduction than a proven pharmaceutical without any pharmacological side effects at all — no respiratory depression, no postoperative agitation, no grogginess, no drug interactions. For children who are already taking other medications, or for families with concerns about exposing their child to sedatives, VR offers a genuinely different category of intervention.
The limitation is practical: VR requires equipment, trained staff to set it up, and cooperative patients old enough to engage with the technology. A panicking three-year-old is unlikely to sit still for a headset fitting. There is also the question of scalability — most hospitals do not yet have VR systems integrated into their preoperative workflows, and the upfront cost and staff training represent barriers to adoption. For older adults, particularly those with cognitive impairment, VR’s applicability is less clear. Dementia patients may find a headset disorienting rather than calming, and the technology assumes a level of engagement and sensory processing that may not be intact. Non-pharmacologic alternatives in this population more often involve familiar music, the presence of a known caregiver, or environmental modifications to the preoperative space — approaches that are harder to study in randomized trials but no less important in practice.
Where Ketamine Fits — and Why It Is Not the First Choice
Ketamine has long been used in emergency and battlefield medicine for its rapid onset and dissociative properties. In pediatric patients, it showed superior sedation depth and faster onset compared to midazolam, which might seem like an obvious advantage. But ketamine also carried higher side effects and longer recovery times, making it a poor fit for routine preoperative anxiolysis where the goal is a calm, cooperative child — not a deeply dissociated one.
The side-effect profile includes hallucinations, nausea, and emergence reactions that can be frightening for children and their families. In the context of dementia care, where patients may already experience perceptual disturbances, adding a dissociative agent carries particular risk. Ketamine remains a valuable tool in specific clinical scenarios — procedural sedation in the emergency department, for instance, or cases where other agents have failed — but it occupies a different niche than the preoperative anxiety reduction that dexmedetomidine and other alternatives are targeting.
What the Shift Away From Midazolam Means for Surgical Care Going Forward
The accumulating evidence against midazolam as the default preoperative anxiolytic is beginning to change practice, though slowly. Dexmedetomidine is increasingly available in intranasal formulations that are easy to administer, and anesthesiology departments at academic medical centers are already incorporating it into protocols — particularly for children over six and for adults with respiratory risk factors. The next wave of research will likely focus on optimal dosing, combination approaches that pair low-dose dexmedetomidine with non-pharmacologic interventions like VR or guided imagery, and head-to-head comparisons in populations that have been underrepresented in trials so far, including elderly patients with dementia.
For families and caregivers, the practical takeaway is that midazolam is no longer the only evidence-based option, and it is reasonable to ask an anesthesiologist about alternatives before a scheduled procedure. This is especially true for patients who have had paradoxical reactions to benzodiazepines in the past, those with existing cognitive impairment, or children who experienced severe postoperative agitation after a previous surgery. The conversation does not need to be adversarial — most anesthesiologists are aware of this research and welcome the chance to tailor their approach to the individual patient.
Conclusion
Dexmedetomidine has emerged as the most evidence-supported alternative to midazolam for pre-surgery anxiety, with meta-analyses showing higher rates of satisfactory sedation, dramatically lower postoperative agitation, and reduced need for rescue medications. Its advantages are clearest in children over six and in adults where respiratory and hemodynamic stability matter. Other alternatives occupy specific niches — pregabalin for reducing overall anesthetic requirements, gabapentin for highly anxious patients, and VR for children old enough to engage with immersive technology — while melatonin, despite its safety and cost advantages, has been shown inferior to midazolam in the most rigorous trial to date.
The most important step any patient or caregiver can take is to have a direct conversation with the anesthesia team before the day of surgery. Ask what premedication is planned, whether alternatives are available, and what the expected side effects are given the patient’s specific medical history. For older adults with cognitive concerns or children with a history of difficult surgical experiences, this conversation is not optional — it is an essential part of surgical planning that can shape the entire trajectory of recovery.
Frequently Asked Questions
Is dexmedetomidine approved for preoperative use in children?
Dexmedetomidine is FDA-approved for sedation in adults in intensive care settings, and its use as a preoperative anxiolytic in children is considered off-label. However, a substantial body of randomized trial evidence supports its intranasal use in pediatric premedication, and many children’s hospitals have adopted it into practice protocols. Off-label does not mean unsupported — it means the formal regulatory approval has not caught up with the clinical evidence.
Can melatonin still help with pre-surgery anxiety even though the MAGIC trial showed it was inferior?
Melatonin may help with general sleep quality and nighttime anxiety in the days before a procedure, but the MAGIC trial demonstrated it does not reduce acute preoperative anxiety as effectively as midazolam when given as a direct premedication. Its lower side-effect rate and lower cost are real advantages, but they do not compensate for reduced efficacy in the moments that matter most — parent separation and anesthesia induction.
Does age matter when choosing between dexmedetomidine and midazolam?
Yes, significantly. Research has shown that in preschool children ages two to six, midazolam actually provided more effective anxiety relief than dexmedetomidine. The benefits of dexmedetomidine were more pronounced in older children. This means the best choice depends on the patient’s age, and a one-size-fits-all approach is not supported by the evidence.
Are there non-medication options that actually work for pre-surgery anxiety?
A 2024 randomized controlled trial found that an interactive VR game produced significantly lower anxiety scores than midazolam in children ages five to eleven undergoing tonsillectomy. This is a genuine pharmacologic-free option, though it requires appropriate equipment, cooperative patients, and may not be available at all facilities. For older adults or patients with cognitive impairment, familiar music and caregiver presence during the preoperative period are commonly used non-pharmacologic strategies, though they have less rigorous trial data behind them.
Why is postoperative agitation a concern with midazolam?
Studies have found postoperative agitation rates of approximately 40% with midazolam compared to around 10% with dexmedetomidine. Postoperative agitation can involve thrashing, crying, confusion, and combativeness in the recovery room. Beyond being distressing for patients and families, it can dislodge IV lines, surgical dressings, or drains, creating genuine safety risks. For patients with dementia, postoperative agitation can also trigger prolonged delirium that extends well beyond the immediate recovery period.
You Might Also Like
- The Medication Causing Birth Defects That Doctors Still Prescribe
- The Dog Medication That Humans Are Actually Taking for Pain
- How to Get Brand Name Medication for Free — A Pharmacist Explains
For more, see Alzheimer’s Association — clinical trials.
